Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bit Digital Inc (BTBT) vs 10X Genomics Inc (TXG) Price & Performance

Bit Digital IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Bit Digital Inc vs 10X Genomics Inc — how do they compare? Bit Digital Inc trades at $1.44 (market cap $471.05M), while 10X Genomics Inc trades at $56.98 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 16.2× Bit Digital Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.

BTBTTXG
Market Cap
$471.05M$7.61B
Sector
TechnologyHealth
52-Week High
$4.22$58.57
52-Week Low
$1.23$11.34
Enterprise Value
$760.36M$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bit Digital Inc

BTBT trades at $1.44, up 10.77% over 24 hours, but faces a bearish technical outlook with 14 sell signals against 2 buy signals. The company reported a net loss of $80.32 million in 2025, with a negative net income margin of -145.45%, though it maintains a gross profit margin of 55.57%. Recent earnings have been mixed, with a beat in Q3 2025 but misses in subsequent quarters. The stock is closely watched by investors ahead of its Q2 2026 earnings release on August 13, 2026.

The outlook is challenged by persistent losses and negative cash flow from operations, offset by strong financing inflows. Analyst consensus is bullish with a 100% buy rating from two firms and a $5.12 average price target, suggesting significant upside potential if the company can improve profitability. Key risks include execution challenges, competitive pressures, and reliance on external financing to sustain operations.

10X Genomics Inc

TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bit Digital Inc

Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.

Read more on BTBT

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG